Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort… Read More
News Release | This research study is an important step toward freeing diabetic patients from daily insulin injections and immune suppressing drugs. Researchers from the University of British Columbia (UBC)… Read More
In patients with moderate to severe Crohn’s disease who achieved clinical response to upadacitinib induction treatment, a significantly greater proportion treated with either 15 mg or 30 mg of upadacitinib achieved… Read More
DUBLIN– Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Dara Mann, vice president, marketing, ophthalmology, has been named a 2022 Healthcare Businesswomen’s Association (HBA) Rising Star. Mann was honored at… Read More
VANCOUVER, B.C. – Willow Biosciences Inc. (“Willow” or the “Company”) (TSX: WLLW; OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of high-value molecules traditionally derived from plants, announces… Read More
